Picture of Zymeworks logo

ZYME — Zymeworks News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapMomentum Trap

Zymeworks Inc expected to post a loss of 40 cents a share - Earnings Preview

* Zymeworks Inc  ZYME.OQ   ZYME.O  is expected to show a
fall in
quarterly revenue when it reports  results on October 31 for the
period ending September 30 2024
    * The Middletown Delaware-based  company is expected to
report a
7.3% decrease in revenue to $15.303 million from $16.51 million
a year ago, according to the mean estimate from 7 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Zymeworks Inc is for a
loss
of 40 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Zymeworks
Inc is
14.00​, above​ its last closing price of $13.24. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024              -0.32      -0.27     Beat    14.7
 Mar. 31 2024              -0.29      -0.42     Missed  -44.8
 Dec. 31 2023  -0.46       -0.43      -0.20     Beat    53.9​
 Jan. 1 0001   -0.50       -0.47      -0.41     Beat    12.7
 ​​Jun.        -0.49       -0.47      -0.76     Missed  -61.6
 30 2023                                                
 Jan. 1 0001   -0.55       -0.54      -0.36     Beat    32.9​
 Dec. 31 2022  4.44        4.84       4.65      Missed  -3.9
 Jan. 1 0001   -0.91       -0.92      -0.72     Beat    21.8
 This summary was machine generated October 29 at 21:05 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on Zymeworks

See all news